ArticleProceedings. IEEE International Conference on Bioinformatics and Biomedicine2023
Clinical Assessment of Pneumocystosis with MIMIC Data.
Article in Proceedings. IEEE International Conference on Bioinformatics and Biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pneumocystosis remains a life-threatening disease with a high mortality rate. It's critical to understand its clinical course and risk factors for better disease management. In this retrospective analysis, we aimed to elucidate the prognostic determinants of in-hospital mortality among patients diagnosed with pneumocystosis. Data were extracted from the Medical Information Mart for Intensive Care (MIMIC)-IV database, encompassing all recorded cases of pneumocystosis. The dataset included patient admission records, comprehensive laboratory results, and medication administration data, which were meticulously analyzed to identify relevant features. Employing logistic regression and random forest, we discerned that the administration of micafungin sodium and vasopressin have significant impacts as risk factors on the survival rate of pneumocystosis patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.